Amphastar Pharmaceuticals, Inc. (AMPH)
USD 24.5
(2.6%)
USD 24.5
(2.6%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 644.39 Million USD | 29.14% |
| 2022 | 498.98 Million USD | 13.98% |
| 2021 | 437.76 Million USD | 25.13% |
| 2020 | 349.84 Million USD | 8.53% |
| 2019 | 322.35 Million USD | 9.4% |
| 2018 | 294.66 Million USD | 22.69% |
| 2017 | 240.17 Million USD | -5.87% |
| 2016 | 255.16 Million USD | 1.45% |
| 2015 | 251.51 Million USD | 19.51% |
| 2014 | 210.46 Million USD | -8.37% |
| 2013 | 229.68 Million USD | 12.41% |
| 2012 | 204.32 Million USD | 72.63% |
| 2011 | 118.35 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 171.83 Million USD | -3.52% |
| 2024 Q2 | 182.39 Million USD | 6.14% |
| 2023 Q2 | 145.71 Million USD | 4.06% |
| 2023 Q3 | 180.55 Million USD | 23.91% |
| 2023 Q4 | 178.1 Million USD | -1.36% |
| 2023 Q1 | 140.02 Million USD | 3.7% |
| 2023 FY | 644.39 Million USD | 29.14% |
| 2022 Q4 | 135.02 Million USD | 12.4% |
| 2022 Q1 | 120.36 Million USD | -0.43% |
| 2022 Q2 | 123.46 Million USD | 2.57% |
| 2022 Q3 | 120.12 Million USD | -2.7% |
| 2022 FY | 498.98 Million USD | 13.98% |
| 2021 Q1 | 103.02 Million USD | 7.4% |
| 2021 Q4 | 120.88 Million USD | 7.74% |
| 2021 Q3 | 112.19 Million USD | 10.36% |
| 2021 FY | 437.76 Million USD | 25.13% |
| 2021 Q2 | 101.66 Million USD | -1.32% |
| 2020 Q4 | 95.92 Million USD | 14.97% |
| 2020 Q2 | 85.8 Million USD | 1.32% |
| 2020 Q3 | 83.43 Million USD | -2.77% |
| 2020 FY | 349.84 Million USD | 8.53% |
| 2020 Q1 | 84.68 Million USD | 1.57% |
| 2019 Q1 | 79.79 Million USD | -11.04% |
| 2019 Q3 | 80.13 Million USD | 1.38% |
| 2019 FY | 322.35 Million USD | 9.4% |
| 2019 Q4 | 83.38 Million USD | 4.05% |
| 2019 Q2 | 79.04 Million USD | -0.93% |
| 2018 Q2 | 71.04 Million USD | 21.66% |
| 2018 FY | 294.66 Million USD | 22.69% |
| 2018 Q4 | 89.69 Million USD | 18.73% |
| 2018 Q3 | 75.54 Million USD | 6.34% |
| 2018 Q1 | 58.39 Million USD | -3.33% |
| 2017 Q1 | 56.67 Million USD | -10.82% |
| 2017 Q4 | 60.4 Million USD | 4.29% |
| 2017 Q3 | 57.91 Million USD | -11.15% |
| 2017 Q2 | 65.18 Million USD | 15.03% |
| 2017 FY | 240.17 Million USD | -5.87% |
| 2016 FY | 255.16 Million USD | 1.45% |
| 2016 Q4 | 63.54 Million USD | -1.06% |
| 2016 Q3 | 64.22 Million USD | -5.6% |
| 2016 Q2 | 68.03 Million USD | 14.6% |
| 2016 Q1 | 59.36 Million USD | -22.81% |
| 2015 Q1 | 56.88 Million USD | 1.81% |
| 2015 FY | 251.51 Million USD | 19.51% |
| 2015 Q4 | 76.91 Million USD | 20.42% |
| 2015 Q3 | 63.86 Million USD | 18.6% |
| 2015 Q2 | 53.85 Million USD | -5.33% |
| 2014 Q1 | 45.87 Million USD | -16.41% |
| 2014 Q2 | 49 Million USD | 6.83% |
| 2014 FY | 210.46 Million USD | -8.37% |
| 2014 Q4 | 55.87 Million USD | -6.42% |
| 2014 Q3 | 59.71 Million USD | 21.85% |
| 2013 FY | 229.68 Million USD | 12.41% |
| 2013 Q1 | 52.96 Million USD | 1.75% |
| 2013 Q2 | 62.52 Million USD | 18.05% |
| 2013 Q3 | 59.31 Million USD | -5.13% |
| 2013 Q4 | 54.87 Million USD | -7.49% |
| 2012 FY | 204.32 Million USD | 72.63% |
| 2012 Q4 | 52.05 Million USD | 0.0% |
| 2011 FY | 118.35 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Esperion Therapeutics, Inc. | 116.33 Million USD | -453.918% |
| Theratechnologies Inc. | 81.76 Million USD | -688.116% |
| Safety Shot Inc | 202.67 Thousand USD | -317852.83% |
| Cosmos Health Inc. | 53.37 Million USD | -1107.255% |
| Cronos Group Inc. | 88.84 Million USD | -625.336% |
| Ironwood Pharmaceuticals, Inc. | 442.73 Million USD | -45.549% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Organogenesis Holdings Inc. | 433.14 Million USD | -48.773% |
| Universe Pharmaceuticals INC | 32.3 Million USD | -1894.492% |
| ProPhase Labs, Inc. | 44.38 Million USD | -1351.863% |
| Sonoma Pharmaceuticals, Inc. | 12.73 Million USD | -4960.031% |
| Dynavax Technologies Corporation | 232.28 Million USD | -177.417% |
| Radius Health, Inc. | 2.88 Billion USD | 77.642% |
| China SXT Pharmaceuticals, Inc. | 1.92 Million USD | -33314.364% |
| Alvotech | 91.43 Million USD | -604.765% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | -2574.639% |
| Alpha Teknova, Inc. | 36.68 Million USD | -1656.611% |
| Intra-Cellular Therapies, Inc. | 464.37 Million USD | -38.768% |
| SCYNEXIS, Inc. | 140.14 Million USD | -359.819% |
| Harrow Health, Inc. | 130.19 Million USD | -394.954% |
| Biofrontera Inc. | 34.07 Million USD | -1791.33% |
| DURECT Corporation | 8.54 Million USD | -7438.547% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | -6.07% |
| ANI Pharmaceuticals, Inc. | 486.81 Million USD | -32.369% |
| OptiNose, Inc. | 70.98 Million USD | -807.765% |
| RedHill Biopharma Ltd. | 6.51 Million USD | -9793.718% |
| Aquestive Therapeutics, Inc. | 50.58 Million USD | -1173.936% |
| Cumberland Pharmaceuticals Inc. | 39.55 Million USD | -1529.214% |
| SIGA Technologies, Inc. | 139.91 Million USD | -360.554% |
| Lifecore Biomedical, Inc. | 128.26 Million USD | -402.409% |
| Shineco, Inc. | 9.8 Million USD | -6474.214% |
| Phibro Animal Health Corporation | 1.01 Billion USD | 36.68% |
| Procaps Group S.A. | 409.92 Million USD | -57.2% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -49392.704% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Viatris Inc. | 15.42 Billion USD | 95.823% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | -2574.639% |
| Rockwell Medical, Inc. | 83.61 Million USD | -670.697% |
| Incannex Healthcare Limited | 12 Thousand USD | -5369858.333% |
| Aytu BioPharma, Inc. | 81 Million USD | -695.53% |
| Tilray Brands, Inc. | 788.94 Million USD | 18.322% |
| Collegium Pharmaceutical, Inc. | 566.76 Million USD | -13.697% |
| PetIQ, Inc. | 1.1 Billion USD | 41.523% |
| Silver Spike Investment Corp. | 11.72 Million USD | -5397.25% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 65.853% |
| Journey Medical Corporation | 79.18 Million USD | -713.825% |
| Alimera Sciences, Inc. | 80.75 Million USD | -697.973% |
| Petros Pharmaceuticals, Inc. | 5.82 Million USD | -10967.538% |
| Assertio Holdings, Inc. | 152.06 Million USD | -323.752% |
| Shuttle Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Embecta Corp. | 1.12 Billion USD | 42.506% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -59765.478% |
| Procaps Group, S.A. | 409.92 Million USD | -57.2% |
| PainReform Ltd. | - USD | -Infinity% |
| Avadel Pharmaceuticals plc | 27.96 Million USD | -2204.456% |
| Hempacco Co., Inc. | 4.04 Million USD | -15828.147% |
| Talphera, Inc. | 651 Thousand USD | -98885.407% |
| Pacira BioSciences, Inc. | 674.97 Million USD | 4.531% |
| Alvotech | 91.43 Million USD | -604.765% |
| Lantheus Holdings, Inc. | 1.29 Billion USD | 50.295% |
| Kamada Ltd. | 144.75 Million USD | -345.151% |
| Indivior PLC | 1.09 Billion USD | 41.043% |
| Currenc Group, Inc. | 53.25 Million USD | -1110.01% |
| Evoke Pharma, Inc. | 5.18 Million USD | -12338.545% |
| Flora Growth Corp. | 76.07 Million USD | -747.097% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -59765.478% |
| Evolus, Inc. | 202.08 Million USD | -218.873% |
| HUTCHMED (China) Limited | 837.99 Million USD | 23.103% |
| Akanda Corp. | 2.16 Million USD | -29732.384% |